Physician profile
Mohsin R Khalique
NPI 1124083589
$19,535.90
in general payments reported to CMS, 2019-2025
30 companies · $4,022 in 2025
The $4,022 reported for 2025 was more than what 97% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,241 · 2020: $1,384 · 2021: $2,906 · 2022: $2,755 · 2023: $2,418 · 2024: $3,810 · 2025: $4,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,409 · Consulting Fee: $608 · Education: $234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,408.76 |
| Consulting Fee | $607.50 |
| Education | $233.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $3,516.18 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $1,917.74 | 2019-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $1,598.93 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Lundbeck LLC | $1,546.39 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $1,533.73 | 2019-2025 | Trintellix, Rixubis |
| Abbvie INC. | $1,427.36 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,368.92 | 2020-2025 | Caplyta |
| Axsome Therapeutics, INC. | $1,052.81 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $808.58 | 2019-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $768.27 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $574.74 | 2019-2022 | |
| Corium, LLC | $513.38 | 2022-2024 | Azstarys |
| Vanda Pharmaceuticals INC. | $469.73 | 2019-2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $453.37 | 2019-2025 | Uzedy, Austedo Xr |
| Bausch Health US, LLC | $429.58 | 2019-2025 | Aplenzin, Wellbutrin |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $253.08 | 2019-2025 | Dyanavel Xr |
| Allergan, INC. | $234.83 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $157.89 | 2021-2024 | Qelbree |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $130.82 | 2024-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $126.63 | 2019 | |
| Shire North American Group INC | $124.36 | 2019 | |
| Neuronetics, INC. | $113.59 | 2022-2023 | Neurostar Tms Therapy System |
| Adlon Therapeutics L.P. | $111.19 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $61.04 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $60.76 | 2019 | |
| Merck Sharp & Dohme LLC | $49.29 | 2019-2022 | |
| Biogen, INC. | $41.14 | 2025 | Zurzuvae |
| Eisai INC. | $33.29 | 2021 | |
| Almatica Pharma LLC | $30.63 | 2021 | |
| Abbott Laboratories | $27.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohsin Khalique listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.